

**Original article:**

**ASSOCIATION OF THE VIRULENCE FACTORS OF HELICOBACTER  
PYLORI AND GASTRIC MUCOSAL INTERLEUKIN-17/23 MRNA  
EXPRESSION IN DYSPEPTIC PATIENTS**

Nader Bagheri<sup>1</sup>, Ghorbanali Rahimian<sup>2</sup>, Loghman Salimzadeh<sup>1</sup>, Fatemeh Azadegan<sup>1</sup>,  
Mahmoud Rafieian-Kopaei<sup>3</sup>, Afshin Taghikhani<sup>2</sup>, Hedayatollah Shirzad<sup>1\*</sup>

1 Cellular and Molecular Research Center, Shahrekord University of Medical Sciences

2 Dept. of Internal Medicine, Shahrekord University of Medical Sciences

3 Medical Plants Research Center, Shahrekord University of Medical Sciences, Shahrekord,  
Iran<sup>4</sup>

\* corresponding author E-mail address: [shirzad1951@yahoo.com](mailto:shirzad1951@yahoo.com) or  
[shirzadeh@SKUMS.ac.ir](mailto:shirzadeh@SKUMS.ac.ir)

**ABSTRACT**

The molecular pathways that control *Helicobacter pylori* (Hp)-associated inflammatory reaction are complex, but locally induced cytokines and virulence factors seem to have a major role in maintaining the ongoing inflammation. Therefore this study was aimed to evaluate the association of the virulence factors of Hp and gastric mucosal interleukin-17/23 mRNA expression in dyspeptic patients.

Mucosal IL-17 and IL-23 mRNA expression in *H. pylori* infected and non-infected gastric biopsies were determined by real-time RT-PCR. Virulence factors, *vacA* and *cagA* were evaluated using PCR.

There was no significant difference in mucosal IL-17 and IL-23 mRNA expression between *H. pylori* infected and non-infected patients. Their expression in mucosa did not correlate with chronic gastritis and chronic active gastritis. IL-17 and IL-23 mRNA expression in mucosa of patients with *vacA* m1 were significantly higher than those observed in patients with *vacA* m2. The severity of polymorphonuclear infiltration and chronic active gastritis was higher in *cagA*-positive than *cagA*-negative patients.

*H. pylori* infections carrying the *vacA* m1 allele have higher IL-17 and IL-23 mRNA and the current study suggests that the virulence factor *vacA* allele's m1 are important for the severe gastric inflammation.

**Keywords:** *H. pylori*, virulence factor, interleukin, gastritis

**INTRODUCTION**

*H. pylori* is a spiral-shaped Gram-negative flagellate bacterium that colonizes the gastric mucosa of approximately 50 % of the world's population. Although its colonization often stays asymptomatic, but can progress into gastric or duodenal ulcers, gastric malignancies and mucosa-associated

lymphoid tissue lymphomas (Fox and Wang, 2007). Hp-associated inflammatory reaction is defined by a massive mucosal infiltration of polymorphonuclear leukocytes (PMN), T cells, macrophages, and plasma cells (Avilés-Jiménez et al., 2012). The ability of Hp to cause disease is thought to attribute to complex interplay between host genetic factors, environmental

and bacterial factors. *H. pylori* adheres to the cells of gastric epithelial and secretes effector molecules that can change gastric epithelial cell function and viability (Ernst and Gold, 2000; Chatterjee et al., 2012). These changes enhance production of cytokines, which are involved in gastric inflammation and epithelial cell damage (Avilés-Jiménez et al., 2012). Moreover, Hp infection elicits a noticeable mucosal accumulation of T lymphocytes, which is responsible to gastric pathology by synthesizing T helper (Th) 1-type cytokines, such as IFN- $\gamma$  and TNF- $\alpha$  (D'Elis et al., 1997; Ernst and Gold, 2000; Hitzler et al., 2012). Recently, a novel pathway of inflammation characterized by excessive production of IL-17 has been reported to be involved in the pathogenesis of immune-mediated diseases, such as rheumatoid arthritis, experimental autoimmune encephalomyelitis, and psoriasis (Kolls and Linden, 2004; Steinman, 2007). IL-17 consists of a family of related cytokines (IL-17A–F), IL-17-producing cells termed Th17 cells. These cells also produce TNF- $\alpha$ , IL-6, IL-22, and granulocyte macrophage-colony stimulating factor (Kolls and Linden, 2004; Park et al., 2005; Steinman, 2007; Weaver et al., 2007). IL-17 stimulates the synthesis of IL-1 $\beta$ , IL-6, TNF- $\alpha$ , PGE<sub>2</sub>, ICAM-1 and cyclo-oxygenase-2 (Fossiez et al., 1998; Griffin et al., 2012; Serelli-Lee et al., 2012). Thus, IL-17 seems to provide a link between T cell activation and inflammatory responses. In spite of marked Th (Placeholder 1) cell response, Hp-colonized gastric mucosa also contains high levels of IL-17 (Luzza et al., 2000; Mizuno et al., 2005). The synthesis of IL-8 by gastric mononuclear and epithelial cells is positively regulated by IL-17, thus emphasizing the potential role of IL-17 in the Hp-driven inflammation (Luzza et al., 2000). However, the factors involved in the control of IL-17 production in Hp-associated gastritis are yet unclear.

IL-23 is a heterodimeric protein that is composed of a specific IL-23p19 subunit and IL-12p40 subunit. This cytokine is pri-

marily produced by activated dendritic cells, monocytes and macrophages (Oppmann et al., 2000). IL-23/p19-null mice have reduced numbers of Th17 cells, thus confirming the role of IL-23 in enhancing IL-17 production (Ghildardi et al., 2004). The clinical outcome of *H. pylori* infection is suggested to be linked to certain strains such as the cytotoxin-associated gene (*cagA*) and vacuolating cytotoxin (*vacA*). The *cagA* gene which is a marker for the presence of a Pathogenicity Island (CagPAI), has been shown to be involved in induction of proinflammatory chemokine released.

The *vacA* gene has a mosaic structure and comprised signal (s) and middle (m) regions (Stathis et al., 2009). The s region consists of any one of four signal sequences (type s1a, s1b, s1c or s2), while the m region consists of two middle region alleles (type m1 or m2) (Stathis et al., 2009). The s1 subtype and m1 subtype have been linked to more severe clinical manifestation (Dong et al., 2008; Ferrand et al., 2008; Kuo et al., 2008; Stathis et al., 2009). *CagA* is present in more than 50 % of the *H. pylori* strains and encodes the *cagA* protein. It is a marker of the presence of the Pathogenicity Island, (Swisher and Barbati, 2007; De Luca et al., 2008) is related to virulence of the *H. pylori* strain and is associated with peptic ulcer and gastric malignancy in some populations. This study was aimed to evaluate the association of the virulence factors of Hp and gastric mucosal interleukin-17/23 mRNA expression in dyspeptic patients.

## MATERIALS AND METHODS

A total of 58 *H. pylori*-infected gastritis patients 23 men ( $43.43 \pm 3.53$ ) and 35 women ( $40.57 \pm 2.44$ ) were participated in this study. Hp infection was determined by the rapid urease test, PCR 16srRNA, urea and histological examination of biopsies taken from the corpus. Patients were classified as Hp-infected only if the three tests were positive, respectively. Four biopsies were collected from 58 Hp-infected, and used for rapid urease test, histological ex-

amination, assessment of bacterial virulence factors, detection of *H. pylori* and cytokine RNA analysis.

### **Histological examination**

Sections of biopsy specimens were embedded 10 % buffered formalin and stained with hematoxylin and eosin to examine gastritis and with giemsa to detect Hp. The histological severity of gastritis was blindly graded from normal to severe based on the degree of mononuclear cell (MNC) and polymorphonuclear leukocyte (PMN) infiltration, and atrophy according to the Updated Sydney system (Manxhuka-Kerliu et al., 2009) on a four-point scale: 0, no; 1, mild; 2, moderate; and 3, severe changes.

### **PCR amplification**

DNA for polymerase chain reaction (PCR) was extracted using the Bioflux tissue (Bioflux, Japan). Oligonucleotide primers for PCR amplification of specific segments are shown in Table 1. For *vacA* and *cagA* evaluation, the PCR program comprised 35 cycles of denaturation (at 94 °C for 30 s), annealing (at 56 °C for 30 s, extension at 72 °C for 30 s), and one final extension (at 72 °C for 5 min).

### **Quantitative analyses for IL-17 and IL-23 mRNA in the gastric mucosa using real-time RT-PCR**

Total RNA was isolated from whole gastric biopsy specimens using total RNA extraction biozol (bioflux, Japan). An aliquot containing 0.2 µg of total RNA was used for the reverse transcription reaction, which was conducted using the Superscript first-strand cDNA synthesis system (Fermentas, Finland) according to the manufacturer's instructions. The sequences of oligonucleotide primer and probe are shown in Table 2. The quantification of IL-17 and IL-23 mRNA levels was performed using a Rotor-Gene 3000 (Corbett). Q-PCR reactions were performed in a total volume of 25 µl containing 3 µl of synthesized cDNA solution, 12.5 µl of 2x Rotor-Gene Probe PCR Master Mix (Qiagen, Germany), 500 nM of each primer and 250 nM of the TaqMan probe. Amplification program included a pre warming step (10 min at 94 °C), denaturation step (94 °C for 15 s) and an annealing/extension step (60 °C for 60 s).  $\beta$ -actin was quantified as a reference gene to normalize the mRNA expression levels of other genes. The relative quantification of gene expression in each sample was analyzed by the  $2^{-\Delta\Delta Ct}$  method and expressed as the ratio of related gene to  $\beta$ -actin mRNA.

**Table 1:** PCR primers for amplification of *cagA* and *vacA*

Primer designation	Primer sequence	Size of PCR product (bp)	References
<i>vacA</i> m1/m2	<i>vacAmF</i> : 5'-CAATCTGTCCAATCAAGCGAG-3' <i>vacAmR</i> : 5'-GCGTCTAAATAATTCCAAGG-3'	567 bp (m1) 642 bp (m2)	(Kim et al., 2013)
<i>vacA</i> s1/s2	<i>VA1-F</i> : 5'-ATGGAAATACAACAAACACAC-3' <i>VA1-R</i> : 5'-CTGCTTGAATGCGCCAAAC-3'	259 bp (s1) 286 bp (s2)	(Roesler et al., 2011)
<i>CagA</i>	<i>Cag1</i> : 5-ATGACTAACGAACTATTGATC-3 <i>Cag2</i> : 5-CAGGATTTTTGATCGCTTTATT-3	232 bp	(Rasmussen et al., 2012)

**Table 2:** Primer and probe sequences employed in this study

Gene	Primer and probe sequence
$\beta$ -actin	Forward 5-AGCCTCGCCTTTGCCGA-3 Reverse 5-CTGGTGCCTGGGGCG-3 Probe FAM-CCGCCGCCCGTCCACACCCGCC-TAMRA
IL-17A	Forward 5-AATCTCCACCGCAATGAGGA-3 Reverse 5-ACGTTCCCATCAGCGTTGA-3 Probe FAM-CGGCACTTTGCCTCCCAGATCACA-TAMRA
IL-23(p19)	Forward 5-TCAGTGCCAGCAGCTTTCAC-3 Reverse 5-TCTCTTAGATCCATGTGTCCCAC-3 Probe FAM-CTCTGCACACTGGCCTGGAGTGCA-TAMRA


### Statistical analysis

All experiments were performed at least three times. Parametric data are presented as mean and SE and nonparametric data are presented as medians (25–75 % quartiles). Statistical analysis was performed by Mann-Whitney Rank Sum test or nonpaired t test depending on the data set. A p value of <0.05 was accepted as statistically significant.


## RESULTS

### Effect of virulence factors in *H. pylori*-infected on the Mucosal IL-17 and IL-23 mRNA levels in gastric mucosa


In our study, no significant differences were observed between the expression of interleukin 17 and 23 in *Helicobacter pylori* positive and negative patients (Figure 1). Our results showed that in *H. pylori* infected patients; mucosal IL-17 and IL-23 mRNA levels were dependent on the *vacA* (m1 and m2) status. Mucosal IL-17 and IL-23 mRNA expression in gastritis patients with *vacA* (m1)-positive were significantly higher than those observed in gastritis patients with *vacA* (m2) – positive (Figure 2). Mucosal IL-17 and IL-23 mRNA expression in gastritis patients with *vacA* (s1m1)-positive was also significantly higher than those observed in gastritis patients with *vacA* (s1m2)-positive (Figure 3). Also no significant differences were observed between the expression of interleukin 17 and 23 in gastritis patients with *cagA*-positive and *cagA*-negative (Figure 4).




**Figure 1:** Mucosal IL-17 and IL-23 mRNA expression in gastritis patients. RNA was extracted from gastric biopsies of 58 Hp-infected patients, 50 Hp non-infected patients with gastritis and analyzed for IL-17 and IL-23 by real time PCR. Levels are normalized to  $\beta$ -actin. Values are presented as mean  $\pm$  SD of all experiments.



**Figure 2:** Mucosal IL-17 and IL-23 mRNA expression in gastritis patients with vacA-positive. RNA was extracted from gastric biopsies of 14 Hp-infected patients with vacA (m1)-positive, 30 Hp-infected patients with vacA (m2)-positive with gastritis and analyzed for IL-17 and IL-23 by real time PCR. Levels are normalized to  $\beta$ -actin. Values are presented as mean  $\pm$  SD of all experiments.



**Figure 3:** Mucosal IL-17 and IL-23 mRNA expression in gastritis patients with vacA-positive. RNA was extracted from gastric biopsies of 14 Hp-infected patients with vacA (s1m1)-positive, 30 Hp-infected patients with vacA (s1m2)-positive with gastritis and analyzed for IL-17 and IL-23 by real time PCR. Levels are normalized to  $\beta$ -actin. Values are presented as mean  $\pm$  SD of all experiments.



**Figure 4:** Mucosal IL-17 and IL-23 mRNA expression in Hp-infected patients with cagA-positive and cagA-negative. RNA was extracted from gastric biopsies of 37 Hp-infected patients with cagA-positive, 21 Hp-infected patients with cagA-negative and analyzed for IL-17 and IL-23 by real time PCR. Levels are normalized to  $\beta$ -actin. Values are presented as mean  $\pm$  SD of all experiments.

### ***Correlation between virulence factors and gastric mucosal inflammation and types of disease***

Severe polymorphonuclear infiltration and chronic gastritis were significantly higher in gastritis patients with *vacA* (m1)-positive compare to those observed in gastritis patients with *vacA* (m2)-positive. Severe polymorphonuclear infiltration and chronic active gastritis were also significantly higher in gastritis patients with *cagA*-positive compared to those observed in gastritis patients with *cagA*-negative patients (Table 3).

### ***Correlation between Mucosal IL-17 and IL-23 mRNA levels and gastric mucosal inflammation and types of disease***

In those infected with *H. pylori*, IL-17 and IL-23 mRNA expression in mucosa did not correlate with the degree of mononuclear ( $P=0.192$  and  $P=0.471$ ) or polymorphonuclear ( $P=0.279$  and  $P=0.628$ ) cell infiltration, chronic gastritis ( $P=0.192$  and  $P=0.471$ ), or chronic active gastritis

( $P=0.279$  and  $P=0.628$ ) assessed by the Sydney system.

## **DISCUSSION**

In this study we aimed to evaluate the association of the virulence factors of *Hp* and gastric mucosal interleukin-17/23 mRNA expression in patients with gastritis. Our results showed that there was no significant difference between the expression of interleukin 17 and 23 in *Helicobacter pylori* positive and negative patients. That might be related to the presence of gastritis in two groups. The results of the present study showed that mucosal IL-17 and IL-23 mRNA expression were dependent on the *vacA* (m1) status and their expression in patients infected with *vacA* m1-positive strains were significantly higher than those observed in patients with *vacA* m2-positive strains. Until now a similar study has not been done and this is the first report about correlation of *vacA* with IL-17 and IL-23 expression.

**Table 3:** Relationship between histological parameters determined in gastric biopsy specimens and virulence factors

<b>Genotype</b>	<b>No.</b>	<b>Monocuclear infiltration**</b>	<b>Polymorphonuclear infiltration</b>	<b>Chronic gastritis</b>	<b>Chronic active gastritis</b>
<i>cagA</i> (+)	37	1.62 (1-3)	0.94 (1-3)	1.62 (1-3)	0.94 (1-3)
<i>cagA</i> (-)	21	1.88 (1-3)	0.44 (1-3)	1.88 (1-3)	0.44 (1-3)
<i>P</i> *		0.424	0.046	0.424	0.046
<i>vacA</i>					
m1	12	2.08 (1-3)	0.58 (1-3)	2.08 (1-3)	0.58 (1-3)
m2	36	1.56 (1-3)	0.86 (1-3)	1.56 (1-3)	0.86 (1-3)
<i>P</i> *		0.034	0.433	0.034	0.433
s1	38	1.71 (1-3)	0.79 (1-3)	1.71 (1-3)	0.79 (1-3)
s2	7	1.57 (1-3)	0.57 (1-3)	1.57 (1-3)	0.57 (1-3)
<i>P</i> *		0.708	0.202	0.708	0.202
s1m1	14	2.08 (1-3)	0.58 (1-3)	2.08 (1-3)	0.58 (1-3)
s1m2	25	1.50 (1-3)	0.92 (1-3)	1.50 (1-3)	0.92 (1-3)
s2m1	0				
s2m2	9	1.57 (1-3)	0.57 (1-3)	1.57 (1-3)	0.57 (1-3)
<i>P</i> *		0.099	0.222	0.099	0.222

\*Median scores were compared with the Mann–Whitney test.

\*\*The histopathological parameters were scored as: 0, none; 1, mild; 2, moderate; 3, severe

In this study, we determined that the expression of interleukin 17 and 23 in all patients was high. It has been reported that the IL-23–IL-17 axis plays an important role in the development of chronic inflammation and in host defenses against bacterial infection (Gisbert and Calvet, 2011; Kuo et al., 2011; Nakamura et al., 2012). Also vacuolating activity is higher in s1/m1 genotypes than in s1/m2 genotypes, and is absent in s2/m2 genotypes (Ota et al., 2009; Suzuki et al., 2009; Park et al., 2010). Therefore, it can be concluded that vacA s1/m1 strains cause more immune response and are more frequently associated with gastritis.

Considering that expression of interleukins 17 and 23 in patients with vacA m1 exists in chronic gastritis, therefore, the overexpression of these interleukins along with vacA m1 may similarly lead to chronic gastritis. In our study, the relationships between cagA-positive and severe polymorphonuclear infiltration and chronic active gastritis were significantly higher than those observed in patients with cagA-negative. While in Western countries it has been demonstrated that more severe gastric inflammation develops after infection with cagA-positive strains and in Asian countries there is no such difference (Umit et al., 2009; Rathbone and Rathbone, 2011).

It has been reported that in Western countries, cagA-positive status has been associated with the severe outcomes of the infection (Kondo et al., 2009; Lehours et al., 2009; Zullo et al., 2009). It is possible that the relationship between *H. pylori* genotypes and infection with gastric inflammatory response varies in different nations. These variations in the clinical consequences are due to factors such as duration of the infection, inflammatory response of the patient, virulence of *H. pylori* strains, etc. Although our results do not support the correlation of IL-17 and IL-23 with the inflammatory phenotype of *H. pylori* infected patients, but emerging experimental evidence suggests that IL-23/IL-17 pathway is an important dynamic force for existing

gastric inflammation in *H. pylori*-infected patients. However, further studies are needed to establish the exact contribution of each of these cytokines in the *H. pylori*-associated gastric pathology.

## REFERENCES

- Avilés-Jiménez F, Reyes-Leon A, Nieto-Patlán E, Hansen LM, Burgueño J, Ramos IP et al. In vivo expression of helicobacter pylori virulence genes in patients with gastritis, ulcer, and gastric cancer. *Infect Immun* 2012;80:594-601.
- Chatterjee A, Chatterjee S, Bandyopadhyay SK. *H. pylori*-induced gastric ulcer: pathophysiology and herbal remedy. *Int J Biol Med Res* 2012;3:1461-5.
- D'Elis MM, Manghetti M, De Carli M, Costa F, Baldari CT, Burrioni D et al. T helper 1 effector cells specific for *Helicobacter pylori* in the gastric antrum of patients with peptic ulcer disease. *J Immunol* 1997;158:962-7.
- De Luca A, De Falco M, Manente L, Dattilo D, Lucariello A, Esposito V et al. *Helicobacter pylori* heat shock protein B (HspB) localizes in vivo in the gastric mucosa and MALT lymphoma. *J Cell Physiol* 2008;216:78-82.
- Dong G, Liu C, Ye H, Gong L, Zheng J, Li M et al. BCL10 nuclear expression and t(11;18)(q21;q21) indicate nonresponsiveness to *Helicobacter pylori* eradication of Chinese primary gastric MALT lymphoma. *Int J Hematol* 2008;88:516-23.
- Ernst PB, Gold BD. The disease spectrum of *Helicobacter pylori*: the immunopathogenesis of gastroduodenal ulcer and gastric cancer. *Annu Rev Microbiol* 2000;54:615-40.

Ferrand J, Roumanes D, Pitard V, Moreau JF, Megraud F, Lehours P. Modulation of lymphocyte proliferation induced by gastric MALT lymphoma-associated *Helicobacter pylori* strains. *Helicobacter* 2008;13:167-73.

Fossiez F, Banchereau J, Murray R, Van Kooten C, Garrone P, Lebecque S. Interleukin-17. *Int Rev Immunol* 1998;16: 541-51.

Fox JG, Wang TC. Inflammation, atrophy, and gastric cancer. *J Clin Invest* 2007;117: 60-9.

Ghilardi N, Kljavin N, Chen Q, Lucas S, Gurney AL, De Sauvage FJ. Compromised humoral and delayed-type hypersensitivity responses in IL-23-deficient mice. *J Immunol* 2004;172:2827-33.

Gisbert JP, Calvet X. Common misconceptions in the management of *Helicobacter pylori*-associated gastric MALT-lymphoma. *Aliment Pharmacol Ther* 2011;34:1047-62.

Griffin GK, Newton G, Tarrío ML, Bu D, Maganto-García E, Azcutia V et al. IL-17 and TNF- $\alpha$  sustain neutrophil recruitment during inflammation through synergistic effects on endothelial activation. *J Immunol* 2012;188:6287-99.

Hitzler I, Kohler E, Engler DB, Yazgan AS, Müller A. The role of Th cell subsets in the control of *Helicobacter* infections and in T cell-driven gastric immunopathology. *Front Immunol* 2012;3:142.

Kim JJ, Kim N, Hwang S, Kim JY, Kim JY, Choi JY et al. Relationship of interleukin-1 $\beta$  levels and gastroesophageal reflux disease in Korea. *J Gastroenterol Hepatol* 2013;28:90-8.

Kolls JK, Linden A. Interleukin-17 family members and inflammation. *Immunity* 2004;21:467-76.

Kondo T, Oka T, Sato H, Shinnou Y, Washio K, Takano M et al. Accumulation of aberrant CpG hypermethylation by *Helicobacter pylori* infection promotes development and progression of gastric MALT lymphoma. *Int J Oncol* 2009;35: 547-57.

Kuo SH, Yeh PY, Chen LT, Wu MS, Lin CW, Yeh KH et al. Overexpression of B cell-activating factor of TNF family (BAFF) is associated with *Helicobacter pylori*-independent growth of gastric diffuse large B-cell lymphoma with histologic evidence of MALT lymphoma. *Blood* 2008;112:2927-34.

Kuo SH, Weng WH, Chen ZH, Hsu PN, Wu MS, Lin CW et al. Establishment of a novel MALT lymphoma cell line, ma-1, from a patient with t(14;18)(q32;q21)-positive *Helicobacter pylori*-independent gastric MALT lymphoma. *Genes Chromosomes Cancer* 2011;50:908-21.

Lehours P, Zheng Z, Skoglund A, Megraud F, Engstrand L. Is there a link between the lipopolysaccharide of *Helicobacter pylori* gastric MALT lymphoma associated strains and lymphoma pathogenesis? *PLoS One* 2009;4:e7297.

Luzza F, Parrello T, Monteleone G, Sebkova L, Romano M, Zarrilli R et al. Up-regulation of IL-17 is associated with bioactive IL-8 expression in *Helicobacter pylori*-infected human gastric mucosa. *J Immunol* 2000;165:5332-7.

Manxhuka-Kerliu S, Telaku S, Devolli-Disha E, Ahmetaj H, Sahatciu-Meka V, Kerliu A et al. *Helicobacter pylori* gastritis updated Sydney classification applied in our material. *Prilozi* 2009;30:45-60.



Mizuno T, Ando T, Nobata K, Tsuzuki T, Maeda O, Watanabe O et al. Interleukin-17 levels in *Helicobacter pylori*-infected gastric mucosa and pathologic sequelae of colonization. *World J Gastroenterol* 2005; 11:6305-11.

Nakamura S, Sugiyama T, Matsumoto T, Iijima K, Ono S, Tajika M et al. Long-term clinical outcome of gastric MALT lymphoma after eradication of *Helicobacter pylori*: a multicentre cohort follow-up study of 420 patients in Japan. *Gut* 2012;61:507-13.

Oppmann B, Lesley R, Blom B, Timans JC, Xu Y, Hunte B et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. *Immunity* 2000;13: 715-25.

Ota H, Asano N, Yamauchi K, Akamatsu T. [Crucial roles of *Helicobacter pylori* infection in the pathogenesis of gastric cancer and gastric mucosa-associated lymphoid tissue (MALT) lymphoma].(in Jpn). *Rinsho Byori* 2009;57:861-9.

Park H, Li Z, Yang XO, Chang SH, Nurieva R, Wang YH et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. *Nat Immunol* 2005;6:1133-41.

Park HS, Kim YJ, Yang WI, Suh CO, Lee YC. Treatment outcome of localized *Helicobacter pylori*-negative low-grade gastric MALT lymphoma. *World J Gastroenterol* 2010;16:2158-62.

Rasmussen L, Labio RW, Neto AC, Silva L, Queiroz V, Smith M et al. Detection of *Helicobacter pylori* in gastric biopsies, saliva and dental plaques of dyspeptic patients from Marília, São Paulo, Brazil: presence of *vacA* and *cagA* genes. *J Venomous Anim Toxins incl Trop Dis* 2012;18:180-7.

Rathbone M, Rathbone B. *Helicobacter pylori* and gastric cancer. *Recent Results Cancer Res* 2011;185:83-97.

Roesler BM, Costa SCB, Zeitune JMR. Virulence factors of *Helicobacter pylori* and their relationship with the development of early and advanced distal intestinal type gastric adenocarcinoma. In: Tonino P (ed): *Gastritis and gastric cancer - New insights in gastroprotection, diagnosis and treatments* (pp 259-80). Rijeka, Croatia: Tech Publ., 2011.

Serelli-Lee V, Ling KL, Ho C, Yeong LH, Lim GK, Ho B et al. Persistent *Helicobacter pylori* specific Th17 responses in patients with past *H. pylori* infection are associated with elevated gastric mucosal IL-1 $\beta$ . *PLoS One* 2012;7:e39199.

Stathis A, Chini C, Bertoni F, Proserpio I, Capella C, Mazzucchelli L et al. Long-term outcome following *Helicobacter pylori* eradication in a retrospective study of 105 patients with localized gastric marginal zone B-cell lymphoma of MALT type. *Ann Oncol* 2009;20:1086-93.

Steinman L. A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage. *Nat Med* 2007;13:139-45.

Suzuki H, Saito Y, Hibi T. *Helicobacter pylori* and gastric mucosa-associated lymphoid tissue (MALT) lymphoma: updated review of clinical outcomes and the molecular pathogenesis. *Gut Liver* 2009; 3:81-7.

Swisher SC, Barbati AJ. *Helicobacter pylori* strikes again: gastric mucosa-associated lymphoid tissue (MALT) lymphoma. *Gastroenterol Nurs* 2007;30: 348-54; quiz 355-6.

Umit H, Tezel A, Bukavaz S, Unsal G, Otkun M, Soylyu AR et al. The relationship between virulence factors of *Helicobacter pylori* and severity of gastritis in infected patients. *Dig Dis Sci* 2009;54:103-10.

Weaver CT, Hatton RD, Mangan PR, Harrington LE. IL-17 family cytokines and the expanding diversity of effector T cell lineages. *Annu Rev Immunol* 2007;25:821-52.

Zullo A, Hassan C, Andriani A, Cristofari F, De Francesco V, Ierardi E et al. Eradication therapy for *Helicobacter pylori* in patients with gastric MALT lymphoma: a pooled data analysis. *Am J Gastroenterol* 2009;104:1932-7; quiz 1938.